Biotech stocks: So sexy - And so scary

Biotech stocks are up some 40% since late May. Investors, however, would do well to cast a wary eye on this rebound. The science in most companies is extremely exciting - but a long way from making the leap to becoming consistent, product-spawning technology. Plus, the industry is still a bloated mess. In short, biotechnology is inevitably headed for another fall. It is just a question of when. One sure sign the bull run may be ending is the dozen or so startups that have launched initial public offerings.